



Report for the period  
1 January 2022 – 30 September 2022

---

**14<sup>th</sup> November 2022**

---

## Table of contents

|  |    |
|--|----|
| 1. General information about the Company.....  | 3  |
| 1.1 Company details.....   | 3  |
| 1.2 Company profile.....   | 3  |
| 1.3 Management Board.....  | 4  |
| 1.4 Shareholder structure.....   | 5  |
| 1.5 Persons employed.....  | 5  |
| 2. Condensed Standalone Financial Statements .....                                     | 6  |
| 2.1 Condensed Standalone statement of comprehensive income and financial position..... | 6  |
| 2.2 Condensed Standalone statement of cashflow .....                                   | 8  |
| 2.3 Condensed Standalone statement of changes in equity .....                          | 9  |
| 3. Condensed Consolidated Financial Statement .....                                    | 10 |
| 3.1 Condensed Consolidated Statement of comprehensive income.....                      | 10 |
| 3.2 Condensed Statement of financial position .....                                    | 11 |
| 3.3. Condnsed Consolidated Statement of cash flow .....                                | 12 |
| 3.4 Condnsed Consolidated Statement of changes in equity .....                         | 13 |

## 1. General information about the Company

### 1.1 Company details

|               |   |
|---------------|---|
| Company name: | Agroliga Group PLC                                      |
| Seat:         | Nicosia, Cyprus   |
| Address:      | Boumpoulinas, 11, 1st floor, P.C. 1060, Nicosia, Cyprus |
| Telephone:    | +38 (057) 766-50-70                                     |
| Fax:          | +38 (057) 766-50-70                                     |
| E-mail:       | info@agroliga.com.ua                                    |
| www:          | www.agroliga.com.ua                                     |

Source: Issuer

### 1.2 Company profile

Agroliga Group ("Group") is Ukraine based company conducting food and agricultural business. The Group produces sunflower oil and different grains. The Group consists of twelve companies:

- Agroliga Group PLC – the holding company based in Cyprus;
- Agroliga operating in Ukraine. It conducts plant production;
- Mechnikovo operating in Ukraine. It specializes in milk cows breeding and plant production;
- Agrokom Novaya Vodolaga operating in Ukraine. It conducts sunflower oil production;
- Group of Companies Agroliga LLC– the holding company based in Ukraine.
- VostokAgroKontrakt operating in Ukraine. It conducts plant production;
- Mayak operating in Ukraine and conducts plant production. It was added to Group in August 2015.
- Agroliga-Trade LLC operating in Ukraine. It focuses on sales and trading services for other companies in the Group.
- LLC "AGL Energy" - is based in Ukraine, the main activity of the enterprise will be the production and sale of electricity.
- LLC Trading House Liga Trade operating in Ukraine. It focuses on sales and trading services for other companies in the Group.

### 1.3 Management Board

Oleksander Berdnyk - Chairman of the Board of Directors


Bizserve Investments Limited – Member of the Board of Directors

Bizserve Management Limited – Member of the Board of Directors

### 1.4 Shareholder structure

**Table 1 - The Shareholding structure of the Issuer, indicating shareholders holding at least 5% of the votes at the date of report (as of 14/11/2022)**

| Stockholder      | Number of shares | Number of votes at the general meeting | Participation in share capital | Participation in the total number of votes at the general meeting |
|------------------|------------------|--|--------------------------------|---|
| Olexandr Berdnyk | 640 750          | 640 750                                | 41,66%                         | 41,66%  |
| Irina Poplavska  | 640 750          | 640 750                                | 41,66%                         | 41,66%  |
| Free float       | 256 300          | 256 300                                | 16,68%                         | 16,68%  |
| <b>ALL</b>       | <b>1 537 800</b> | <b>1 537 800</b>                       | <b>100%</b>                    | <b>100%</b>   |



- Irina Poplavskaya
- Alexandr Berdnyk
- Others

## 1.5 Persons employed

There are 332 persons employed by Agroliga group as at 14/11/2022 (FTE, including all the Group's companies)

| CATEGORY             | 13/11/2020 |
|----------------------|------------|
| ADMINISTRATION       | 41         |
| PRODUCTION EMPLOYEES | 224        |
| SUPPORT              | 67         |
| TOTAL                | 332        |

## 2. Condensed Standalone Financial Statement for the 3Q2022

Tables below provide condensed interim financial statements of Agroliga Group PLC, in accordance with International Financial Reporting Standards for a 3Q 2022 (period ended 30 September 2022).

All data are presented in thousand EUR.

### 2.1 CONDENSED STANDALONE STATEMENT OF COMPREHENSIVE INCOME AND FINANCIAL POSITION

| Statement of comprehensive income<br>for the period began 01 January ended 30 September 2022 |      |               |               |
|--|------|---------------|---------------|
|  |      | 30 Sept. 2022 | 30 Sept. 2021 |
|  | Note | €000          | €000          |
| <b>Continuing operations</b>   |      |               |               |
| Sales revenue  |      | 2 273         | 157           |
| Loan interest income   |      | 10            | 16            |
| Cost of sales  |      | (2 262)       | -             |
| Profit from investment activities  |      | -             | -             |
| Income from change in fair value of agricultural   |      | -             | -             |
| <b>Gross profit</b>  |      | <b>21</b>     | <b>173</b>    |
| Other operating income/(expenses), net   |      | 3             | -             |
| Net foreign exchange loss  |      | 23            | -             |
| Selling and distribution costs   |      | -             | -             |
| Administrative expenses  |      | (44)          | (185)         |
| <b>Operating profit</b>  |      | <b>2</b>      | <b>(12)</b>   |
| Financial income/(expenses), net   |      | (3)           | (3)           |
| Exchange rate differences, net   |      | -             | -             |
| <b>Profit before tax from continuing operations</b>  |      | <b>(1)</b>    | <b>(15)</b>   |
| Income tax expense   |      | -             | -             |
| <b>Profit for the year from continuing operations</b>  |      | <b>(1)</b>    | <b>(15)</b>   |
| <b>Other comprehensive income for the year</b>   |      | <b>-</b>      | <b>-</b>      |
| Exchange difference on translating foreign operations  |      | -             | -             |
| <b>Total other comprehensive income for the year</b>   |      | <b>-</b>      | <b>-</b>      |
| <b>Total comprehensive income for the year, net of tax</b>                                   |      | <b>(1)</b>    | <b>(15)</b>   |
| <b>Total comprehensive income attributable to</b>  |      |               |               |
| Equity holders of the parent   |      | (1)           | (15)          |
| Non-controlling interest   |      | -             | -             |

Statement of comprehensive financial position for the period ended 30/09/2022 and 30/12/2021

**Statement of financial position**

for the period began 01 January ended 30 September 2022

|  | 30 Sept. 2022 | 31 Dec 2021 |
|--|---------------|-------------|
|  | € 000         | € 000       |
| <b>Assets</b>                          |               |             |
| <b>Non-current assets</b>              |               |             |
| Property, plant and equipment          | -             | -           |
| Investments in subsidiaries            | 112           | 112         |
| <b>Total non-current assets</b>        | <b>112</b>    | <b>112</b>  |
| <b>Current assets</b>                  |               |             |
| Current biological assets              | 0             | 0           |
| Inventories                            | 0             | 0           |
| Loans receivable                       | 2 911         | 386         |
| Cash and cash equivalent               | 25            | 29          |
| <b>Total current assets</b>            | <b>2 936</b>  | <b>415</b>  |
| <b>Total assets</b>                    | <b>3 048</b>  | <b>527</b>  |
| <b>Equity and liabilities</b>          |               |             |
| Share capital                          | 31            | 31          |
| Share premium                          | 953           | 953         |
| Retained earnings (accumulated losses) | (478)         | (479)       |
| <b>Total equity</b>                    | <b>506</b>    | <b>505</b>  |
| <b>Current liabilities</b>             |               |             |
| Trade and other payables               | 2 543         | 22          |
| <b>Total equity and liabilities</b>    | <b>3 049</b>  | <b>527</b>  |

## 2.2 CONDENSED STANDALONE STATEMENT OF CASHFLOW

Statement of cash flows for the period from 01.01.2022 to 30.09.2022

| Statement of cash flows  |      | 30 Sept. 2022 | 30 Sept 2021 |
|--|------|---------------|--------------|
| for the period began 01 January ended 30 September 2022              |      |               |              |
|  | Note | €000          | €000         |
| <b>CASH FLOW FROM OPERATING ACTIVITIES</b>                           |      |               |              |
| <b>Profit before tax</b>   |      | (1)           | (15)         |
| Non-cash adjustment to reconcile profit before tax to net cash flows |      |               |              |
| Depreciation and impairment of property, plant and equipment         |      | -             | -            |
| Unrealised exchange loss/(profit)                                    |      | (23)          | 0            |
| Interest income  |      | (10)          | (16)         |
|  |      | <b>(35)</b>   | <b>(31)</b>  |
| <b>Changes in working capital:</b>                                   |      |               |              |
| (Increase)/decrease trade and other receivables                      |      | (2 525)       | 101          |
| Increase/(decrease) in trade and other payables                      |      | 2 521         | 12           |
| Interest received  |      | 10            | 16           |
| <b>Net cash flows from operating activities</b>                      |      | <b>(28)</b>   | <b>129</b>   |
| <b>CASH FLOW FROM INVESTING ACTIVITIES</b>                           |      |               |              |
| Loans granted  |      | -             | (115)        |
| <b>Net cash flows used in investing activities</b>                   |      | <b>-</b>      | <b>(115)</b> |
| <b>CASH FLOW FROM FINANCING ACTIVITIES</b>                           |      |               |              |
| Unrealised exchange (loss)/profit                                    |      | 23            | (0)          |
| Dividends paid   |      | -             |              |
| <b>Net cash flows from/(used in) financing activities</b>            |      | <b>23</b>     | <b>(0)</b>   |
| Net increase in cash and cash equivalents                            |      | (5)           | 14           |
| <b>Cash and cash equivalents at beginning of the year</b>            |      | <b>29</b>     | <b>2</b>     |
| <b>Cash and cash equivalents at the end of the year</b>              |      | <b>24</b>     | <b>15</b>    |



## 2.3 CONDENSED STANDALONE STATEMENT FOR CHANGES IN EQUITY

Statement of changes in equity for the period from 01.01.2022 ended 30.09.2022

### Statement of changes in equity

for the period began 01 January ended 30 September 2022

|   | Share<br>capital | Share<br>premium | Retained<br>earnings/<br>Accumulated<br>losses | Total        |
|---|------------------|------------------|--|--------------|
| <b>Balance at 31 December 2020/1 January 2021</b>   | <b>31</b>        | <b>953</b>       | <b>(295)</b>                                   | <b>688</b>   |
| Net profit for the year                             | -                | -                | (308)  | 6            |
| Total comprehensive income for the year, net of tax | -                | -                | (308)  | 6            |
| Dividends paid                                      |                  |                  | 492  |              |
| <b>Balance at 31 December 2021</b>                  | <b>31</b>        | <b>953</b>       | <b>479</b>                                     | <b>504</b>   |
| Income for the period                               |                  |                  | -  | 0            |
| Loss for the period                                 | -                | -                | (1)  | (1)          |
| Total comprehensive income for the year, net of tax |                  |                  | (1)  | (1)          |
| <b>Balance at 30 September 2022</b>                 | <b>31</b>        | <b>953</b>       | <b>478</b>                                     | <b>1 461</b> |

### 3. Condensed Financial Statements

Tables below provide data from condensed consolidated interim financial statements, prepared in accordance with International Accounting Standard for 3Q 2022 (period ended September 30, 2022). The condensed consolidated interim financial statements and comprehensive income position as well as consolidated statement for changes in equity present comparative data for 30.09.2022. All data are presented in thousand EUR.

#### 3.1 CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

**Condensed statement of profit or loss and other comprehensive income  
for the period from 01/01 to 30/09 of 2022 year (with comparative data)**

|   | 01/01/2022<br>- 30/09/2022 | 01/01/2021<br>- 30/09/2021 |
|---|----------------------------|----------------------------|
|   | €000                       | €000                       |
| <b>Continuing operations</b>  |                            |                            |
| Sales revenue   | 33 039                     | 47 166                     |
| Cost of sales   | (26 453)                   | (41 107)                   |
| Income (expenses) from change in fair value of biological assets<br>agricultural products | -                          | -                          |
| <b>Gross profit</b>   | <b>6 586</b>               | <b>6 059</b>               |
| Administrative expenses   | (553)                      | (764)                      |
| Distribution expenses   | (2 002)                    | (1 964)                    |
| Other operating income/(expenses), net  | 998                        | 1 525                      |
| <b>Operating profit</b>   | <b>(3 194)</b>             | <b>5 827</b>               |
| Non-operational income/(expenses), net  |                            |                            |
| Financial income/(expenses), net  | (732)                      | (669)                      |
| Exchange rate differences, net  | (4 173)                    | 1640                       |
| <b>Profit before tax from continuing operations</b>                                       | <b>124</b>                 | <b>5 827</b>               |
| Income tax expense  | (32)                       | (10)                       |
| <b>Profit for the year from continuing operations</b>                                     | <b>92</b>                  | <b>5 817</b>               |
| <b>Profit for the year attributable to</b>  |                            |                            |
| Equity holders of the parent  | 88                         | 5 553                      |
| Non-controlling interest  | 4                          | 264                        |

### 3.2 CONDENSED STATEMENT OF FINANCIAL POSITION

#### Condensed statement of financial position

as at 30 September 2022 and 31 December 2021 (with comparative data)

|   | 30 September, 2022 | 31 December, 2021 |
|---|--------------------|-------------------|
|   | €000               | €000              |
| <b>Assets</b>                                       |                    |                   |
| <b>Non-current assets</b>                           |                    |                   |
| Property, plant and equipment                       | 37 772             | 40 337            |
| Right-of-use assets                                 | 1 365              | 1 183             |
| Biological assets                                   | 29                 | 17                |
| Non-current loans receivable                        | -                  |                   |
| Deferred tax assets                                 | 4                  | 7                 |
| <b>Total non-current assets</b>                     | <b>39 170</b>      | <b>41 544</b>     |
| <b>Current assets</b>                               |                    |                   |
| Inventories and work in progress                    | 14 231             | 16 219            |
| Current biological assets                           | 419                | 533               |
| Trade and other receivables                         | 15 132             | 9 542             |
| Cash and cash equivalent                            | 113                | 118               |
| <b>Total current assets</b>                         | <b>29 895</b>      | <b>26 412</b>     |
| <b>Total assets</b>                                 | <b>69 065</b>      | <b>67 956</b>     |
| <b>Equity and liabilities</b>                       |                    |                   |
| Share capital                                       | 31                 | 31                |
| Share premium                                       | 953                | 953               |
| Translation reserve                                 | (17 189)           | (11 561)          |
| Retained earnings                                   | 46 814             | 46 726            |
| Equity attributable to equity holders of the parent | 30 609             | 36 149            |
| Non-controlling interests                           | 3 500              | 3 496             |
| <b>Total equity</b>                                 | <b>34 109</b>      | <b>39 645</b>     |
| <b>Non-current liabilities</b>                      |                    |                   |
| Borrowings  | 3 535              | 3 540             |
| Long-term portion of lease liabilities              | 1 307              | 1 084             |
| Deferred tax liability                              | 1 681              | 1 628             |
| <b>Total non-current liabilities</b>                | <b>6 523</b>       | <b>6 256</b>      |
| <b>Current liabilities</b>                          |                    |                   |
| Trade and other payables                            | 12 769             | 7 519             |

|                                       |               |               |
|---------------------------------------|---------------|---------------|
| Interest-bearing loans and borrowings | 433           | 197           |
| Borrowings                            | 15 199        | 14 263        |
| Provisions                            | 32            | 80            |
| <b>Total current liabilities</b>      | <b>28 433</b> | <b>22 059</b> |
| <b>Total equity and liabilities</b>   | <b>69 065</b> | <b>67 956</b> |

### 3.3 CONDENSED CONSOLIDATED STATEMENT OF CASHFLOW

#### Condensed statement of cash flows for the period ended 30.09.2022 with comparative data

##### Condensed statement of cash flows

for the period from 01/01 to 30/09 of 2022 year

| € '000   | 01/01/2022<br>- 30/09/2022 | 01/01/2021<br>- 30/09/2021 |
|--|----------------------------|----------------------------|
| <b>Cash flows from operating activities</b>                                    |                            |                            |
| <b>Profit before tax</b>   | <b>124</b>                 | <b>5 827</b>               |
| Adjustments for:   |                            |                            |
| Depreciation of property, plant and equipment                                  | 1 409                      | 1 452                      |
| Changes in the reserve of doubtful debts                                       | -                          | -                          |
| Losses/gain on current assets sold   | -                          | -                          |
| Exchange rate differences, net   | 4 173                      | (1 640)                    |
| Income from previously written off assets                                      | -                          | -                          |
| Changes in deferred taxes  | -                          | -                          |
| Income from change in fair value of biological assets                          | -                          | -                          |
| Exchange difference arising on the translation of assets on foreign currencies | -                          | -                          |
| Interest income  | -                          | -                          |
| Interest expense   | 732                        | 669                        |
| <b>Cash flows from operations before working capital changes</b>               | <b>6 438</b>               | <b>6 308</b>               |
| Decrease/(increase) in inventories and work in progress                        | (1 447)                    | (3 203)                    |
| Decrease/(increase) in trade and other receivables                             | (5 590)                    | (4 655)                    |
| Decrease/(increase) in biological assets                                       | 102                        | (608)                      |
| (Decrease)/increase in trade and other payables                                | 1 691                      | 3 697                      |
| <b>Cash flows from operations</b>  | <b>1 194</b>               | <b>1 539</b>               |
| Income tax paid  | (32)                       | (10)                       |
| <b>Net cash flows from operating activities</b>                                | <b>1 162</b>               | <b>1 529</b>               |
| <b>Cash flows from investing activities</b>                                    |                            |                            |
| Payment for purchase of property, plant and equipment                          | (214)                      | (1 129)                    |
| Proceeds from disposal of property, plant and equipment                        | -                          | -                          |
| Loans granted  | -                          | -                          |
| Interest received  | -                          | -                          |
| <b>Net cash flows used in investing activities</b>                             | <b>(214)</b>               | <b>(1 129)</b>             |

**Cash flows from financing activities**

|  |       |         |
|--|-------|---------|
| Proceeds from issue of share capital   | -     | -       |
| Proceeds of borrowings   | 1 400 | 3 392   |
| Repayment of borrowings  | (713) | (3 363) |
| Interest paid  | (732) | (669)   |
| Suspense account (pending correction of Depreciation, Minority interest and share capital) |       |         |

|   |             |              |
|---|-------------|--------------|
| <b>Net cash flows (used in)/from financing activities</b> | <b>(45)</b> | <b>(640)</b> |
| Net increase (decrease) in cash and cash equivalents      | <b>903</b>  | <b>(240)</b> |
| Cash at beginning of the year/period                      | 118         | 183          |
| Effect of exchange rates fluctuations on cash             | (908)       | 267          |
| <b>At end of the year/period</b>                          | <b>113</b>  | <b>210</b>   |

### 3.4 CONDENSED CONSOLIDATED STATEMENT FOR CHANGES IN EQUITY

**Condensed consolidated statement for changes in equity for the period ended 30/09/2022**
**Condensed statement for changes in equity for the period from 01/01 to 30/09 of 2022 year**

|   | Attributable to equity holders of the Company |                  |                        |                      |                                  | Total<br>€000 |
|---|---|------------------|------------------------|----------------------|----------------------------------|---------------|
|   | Share<br>capital                              | Share<br>premium | Translation<br>reserve | Retained<br>earnings | Non-<br>controlling<br>interests |               |
|   | €000  | €000             | €000                   | €000                 | €000                             |               |
| <b>Balance at 31 December 2020</b>                      | <b>31</b>                                     | <b>953</b>       | <b>(7 745)</b>         | <b>36 297</b>        | <b>2 070</b>                     | <b>31 606</b> |
| <b>Balance at 1 January 2021 as previously reported</b> | <b>31</b>                                     | <b>953</b>       | <b>(7 745)</b>         | <b>36 297</b>        | <b>2 070</b>                     | <b>31 606</b> |
| Net profit the period                                   | -   | -                | -                      | 6 360                | 1 768                            | 8 128         |
| Exchange difference on the translation                  | -   | -                | (3 816)                | -                    | -                                | (3 816)       |
| <b>Balance at 31 December 2021/1 January 2022</b>       | <b>31</b>                                     | <b>953</b>       | <b>(11 561)</b>        | <b>46 726</b>        | <b>3 496</b>                     | <b>39 645</b> |
| Net profit the period                                   | -   | -                | -                      | 88                   | 4                                | 92            |
| Exchange difference on the translation                  | -   | -                | (5 628)                | -                    | -                                | (5 628)       |
| <b>Balance at 30 September, 2022</b>                    | <b>31</b>                                     | <b>953</b>       | <b>(17 189)</b>        | <b>46 814</b>        | <b>3 500</b>                     | <b>34 109</b> |

*Source: Issuer*

Statements were prepared according rules of IAS 34. There were no changes in accounting policy of the Group during period 01/01/22-30/09/22. More detailed Group's accounting policy is described in audited annual report of the Group.

Exchange rate effect was noted in Statement of financial position.

Aleksandr Berdnyk  
Chairman of the Board of Directors

